Published in Sci Transl Med on January 23, 2013
Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell (2014) 1.99
Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. Nat Commun (2016) 1.44
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist (2013) 1.42
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med (2016) 1.22
Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest (2014) 1.20
Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. BMC Genomics (2014) 1.16
Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A (2013) 1.12
Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer (2014) 1.11
Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget (2013) 1.07
Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci (2014) 1.05
An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy. Br J Radiol (2014) 1.04
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacol Sin (2015) 0.99
Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer. Oncogene (2015) 0.95
Epigenetic susceptibility factors for prostate cancer with aging. Prostate (2013) 0.94
The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev (2014) 0.94
Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution. PLoS Genet (2016) 0.92
Transcriptional control of cancer metastasis. Trends Cell Biol (2013) 0.92
Intratumoral Heterogeneity of the Epigenome. Cancer Cell (2016) 0.90
The genomic landscape of prostate cancer. Int J Mol Sci (2013) 0.88
Development of a multiplex methylation specific PCR suitable for (early) detection of non-small cell lung cancer. Epigenetics (2014) 0.86
SOX9 drives WNT pathway activation in prostate cancer. J Clin Invest (2016) 0.85
Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer. Epigenetics (2014) 0.83
Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer. Cancer Prev Res (Phila) (2014) 0.83
Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.83
Genomic profiling screens small molecules of metastatic prostate carcinoma. Oncol Lett (2015) 0.82
SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier. PLoS One (2015) 0.81
Components of the canonical and non-canonical Wnt pathways are not mis-expressed in pituitary tumors. PLoS One (2013) 0.81
Prostate cancer: Intrapatient heterogeneity in prostate cancer. Nat Rev Urol (2015) 0.80
Prostate cancer epigenetics and its clinical implications. Asian J Androl (2016) 0.80
Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis. PLoS One (2013) 0.80
DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation. Cell Death Differ (2014) 0.80
Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. Cancer Res (2015) 0.80
DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer. PLoS One (2015) 0.79
Global DNA methylation changes and differential gene expression in Anaplasma phagocytophilum-infected human neutrophils. Clin Epigenetics (2015) 0.79
Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies. PLoS One (2016) 0.79
Promoter hypermethylation profiling of distant breast cancer metastases. Breast Cancer Res Treat (2015) 0.79
Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting. Prostate (2014) 0.78
Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer. Int J Cancer (2016) 0.78
Integrative gene set analysis of multi-platform data with sample heterogeneity. Bioinformatics (2014) 0.78
Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma. Mod Pathol (2015) 0.78
Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis. BMC Syst Biol (2015) 0.77
Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer. PLoS One (2014) 0.77
miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation. Mol Endocrinol (2015) 0.77
Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer. Cancer Res (2015) 0.77
Integrin α9 gene promoter is hypermethylated and downregulated in nasopharyngeal carcinoma. Oncotarget (2015) 0.76
Estimating and accounting for tumor purity in the analysis of DNA methylation data from cancer studies. Genome Biol (2017) 0.75
Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. Sci Rep (2016) 0.75
Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns. BMC Cancer (2017) 0.75
Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma. Genome Med (2016) 0.75
Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biol (2017) 0.75
Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel) (2017) 0.75
Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 gene. Am J Pathol (2015) 0.75
Initiation of aberrant DNA methylation patterns and heterogeneity in precancerous lesions of human hepatocellular cancer. Epigenetics (2017) 0.75
CellMethy: Identification of a focal concordantly methylated pattern of CpGs revealed wide differences between normal and cancer tissues. Sci Rep (2015) 0.75
LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality. Epigenetics (2016) 0.75
In reply. Oncologist (2014) 0.75
Genome-wide predictors of NF-κB recruitment and transcriptional activity. BioData Min (2015) 0.75
DNA methylation: an epigenetic mark of cellular memory. Exp Mol Med (2017) 0.75
Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma. J Invest Dermatol (2015) 0.75
AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nat Commun (2017) 0.75
Biology and evolution of poorly differentiated neuroendocrine tumors. Nat Med (2017) 0.75
An androgen reduced transcript of LncRNA GAS5 promoted prostate cancer proliferation. PLoS One (2017) 0.75
Tumour heterogeneity: principles and practical consequences. Virchows Arch (2016) 0.75
Epigenetic determinants of metastasis. Mol Oncol (2016) 0.75
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
The epigenomics of cancer. Cell (2007) 30.91
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Epigenetics in cancer. N Engl J Med (2008) 17.36
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
Role for DNA methylation in genomic imprinting. Nature (1993) 12.65
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science (1992) 10.12
The epigenetic progenitor origin of human cancer. Nat Rev Genet (2006) 9.65
Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 9.28
Increased methylation variation in epigenetic domains across cancer types. Nat Genet (2011) 8.92
Cyclical DNA methylation of a transcriptionally active promoter. Nature (2008) 7.62
CpG island methylator phenotype in cancer. Nat Rev Cancer (2004) 7.13
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Transient cyclical methylation of promoter DNA. Nature (2008) 5.19
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res (2001) 4.51
Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol (2009) 4.43
Landscape of somatic retrotransposition in human cancers. Science (2012) 4.37
Purification of CpG islands using a methylated DNA binding column. Nat Genet (1994) 4.31
Suppression of intestinal neoplasia by DNA hypomethylation. Cell (1995) 4.16
Personalized epigenomic signatures that are stable over time and covary with body mass index. Sci Transl Med (2010) 3.81
Hypomethylation of DNA from benign and malignant human colon neoplasms. Science (1985) 3.72
The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res (1983) 3.51
An elaborate pathway required for Ras-mediated epigenetic silencing. Nature (2007) 3.47
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucleic Acids Res (2009) 3.29
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
Epigenetic dynamics of stem cells and cell lineage commitment: digging Waddington's canal. Nat Rev Mol Cell Biol (2009) 3.12
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol (2010) 2.38
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
Allele-specific DNA methylation: beyond imprinting. Hum Mol Genet (2010) 1.98
Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell (2012) 1.91
DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res (2011) 1.85
Role of DNA 5-methylcytosine transferase in cell transformation by fos. Science (1999) 1.83
Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic Mice. Cancer Res (2002) 1.73
Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J (1999) 1.73
Visualization of genomic data with the Hilbert curve. Bioinformatics (2009) 1.69
A novel role of myosin VI in human prostate cancer. Am J Pathol (2006) 1.59
Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A (2002) 1.53
Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat Genet (2003) 1.44
Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation. Nucleic Acids Res (2006) 1.36
Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res (1995) 1.13
Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences. BMC Genomics (2011) 1.00
Genomic imprinting, DNA methylation, and cancer. J Natl Cancer Inst (1994) 0.86
affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics (2004) 32.08
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet (2010) 11.82
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Increased methylation variation in epigenetic domains across cancer types. Nat Genet (2011) 8.92
A simple spreadsheet-based, MIAME-supportive format for microarray data: MAGE-TAB. BMC Bioinformatics (2006) 7.53
Characterization of Pb(In(12)Nb(12))O(3)-Pb(Mg(13)Nb(23))O(3)-PbTiO(3) ferroelectric crystal with enhanced phase transition temperatures. J Appl Phys (2008) 7.49
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Intra-individual change over time in DNA methylation with familial clustering. JAMA (2008) 6.17
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature (2010) 6.06
A benchmark for Affymetrix GeneChip expression measures. Bioinformatics (2004) 5.99
Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics (2014) 5.93
Prostate cancer. N Engl J Med (2003) 5.91
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J Comput Biol (2005) 5.63
Frozen robust multiarray analysis (fRMA). Biostatistics (2010) 5.57
Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells. Nat Genet (2009) 5.52
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Exploration, normalization, and genotype calls of high-density oligonucleotide SNP array data. Biostatistics (2006) 5.20
Travelling waves in the occurrence of dengue haemorrhagic fever in Thailand. Nature (2004) 5.05
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Preprocessing of oligonucleotide array data. Nat Biotechnol (2004) 4.70
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Evolution in health and medicine Sackler colloquium: Stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and disease. Proc Natl Acad Sci U S A (2009) 4.40
The External RNA Controls Consortium: a progress report. Nat Methods (2005) 4.24
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
A gene expression bar code for microarray data. Nat Methods (2007) 4.20
A framework for oligonucleotide microarray preprocessing. Bioinformatics (2010) 3.97
Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol (2014) 3.89
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Personalized epigenomic signatures that are stable over time and covary with body mass index. Sci Transl Med (2010) 3.81
Electromechanical characterization of [Formula: see text] crystals as a function of crystallographic orientation and temperature. J Appl Phys (2009) 3.80
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Removing technical variability in RNA-seq data using conditional quantile normalization. Biostatistics (2012) 3.74
Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med (2002) 3.68
Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol (2012) 3.62
Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol (2008) 3.43
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther (2005) 3.28
Complete set of material constants of Pb(In(12)Nb(12))O(3)-Pb(Mg(13)Nb(23))O(3)-PbTiO(3)single crystal with morphotropic phase boundary composition. J Appl Phys (2009) 3.22
Nucleocytosolic acetyl-coenzyme a synthetase is required for histone acetylation and global transcription. Mol Cell (2006) 3.22
Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med (2012) 3.21
Sequencing technology does not eliminate biological variability. Nat Biotechnol (2011) 3.20
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
BSmooth: from whole genome bisulfite sequencing reads to differentially methylated regions. Genome Biol (2012) 3.13
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov (2011) 2.77